The European Commission (EC) has granted Leqembi (lecanemab) Marketing Authorisation (MA) in the European Union (EU).  The approval makes the medicine the first therapy that targets an underlying cause of Alzheimer’s disease (AD) to be granted a MA in the EU.  Lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!